Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.
Bill would rein in “pharmacy benefit managers,” or PBMs, which have come under fire for driving up prescription drug costs ...
One initiative that has been scrapped would have offered some generic drugs to Medicare enrollees for $2. Meanwhile, the Trump administration has backed off hospice oversight.
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Cigna’s CFO, Brian Evanko, addressed financial and operational updates at the Barclays Healthcare Conference. The company ...
The bill, which encompasses the recommendations of a task force, would regulate pharmacy benefit managers and increase price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback